superior to G-CSF alone based on mean CD34 ؉ cell yield per pheresis, adequate CD34
/kg and CD34
+ plasma cells may be recruited into the peripheral blood after 1.05 (0.32-3.4) × 10 6 /kg (P = 0.02). The median number mobilizing therapy. 9,10 HDT followed by autologous PBPC of aphereses performed in each group was 5 (4-12) with in MM may induce about 40-60% of complete responses a median of 5.24 ± 2.51 in group I and 3 (2-6) with a in previously untreated patients or in first partial response median of 3.1 (±0.91) in group II (P = NS). Hospitalizafter current induction chemotherapy [1] [2] [3] [4] [5] [6] [7] [11] [12] [13] and some ation for PBPC mobilization was required in all patients investigators have found an advantage regarding response in group I and the treatment-related toxicity was rate, duration of response and progression-free survival greater in this group: 12 patients (66%) developed fever when compared with conventional treatment.
11,12
requiring antibiotics during the neutropenic period In spite of the expansion of this strategy, the optimum after HD-CY and six (33%) patients required transschedule for PBPC mobilization in MM patients remains fusion support. After receiving busulfan 12 mg/kg p.o.
controversial. 14- 21 Most experiences include patients harand melphalan 140 mg/m 2 i.v., as the conditioning vested during the hematological recovery after high-dose regimen, the median periods to reach granulocytes chemotherapy followed by hemopoietic growth factors. (Ͼ0.5 ؋ 10 9 /l) and platelet (Ͼ20 ؋ 10 9 /l) engraftment High-dose cyclophosphamide, HD-CY, (4-7 g/m 2 i.v.) folwere 12 and 11 days respectively (ranges 8-20 and 10-lowed by hemopoietic growth factor (GM-CSF or G-CSF)
16) in group I (HD-CY plus GM-CSF group), and 11
have been the most frequently used schedules. 14-21 Howand 13 days respectively (ranges 7-42 and 10-38) in ever, they are not exempt from morbidity and need patient group II (G-CSF group) (P ‫؍‬ NS). In conclusion, these hospitalization in most cases. Moreover, these methods are data suggest that although HD-CY plus GM-CSF is complex because precise timing of apheresis is difficult to predict. Based on these aspects, the proposal of more simplified PBPC mobilization and collection procedures are expenses.
Recent reports suggest the feasibility of mobilizing PBPC mobilization and collection PBPC in MM patients with G-CSF administered alone PBPC mobilization was performed by two methods: In group without previous myelosuppressive chemotherapy. [22] [23] [24] I (18 patients) the progenitor cells were mobilized with highThis strategy has also been applied successfully as a PBPCdose cyclophosphamide (HD-CY), 4 g/m 2 i.v. divided in 2-priming regimen in patients with other poor-risk maligday infusions through a central venous catheter. Hyperhydnancies. [25] [26] [27] Although some authors have pointed out the ration (4 l continuous infusion over 24 h) was initiated 12 h lower stem cell content provided by this approach when before chemotherapy. MESNA (Uromitexan; Asta Medica, compared with chemotherapy followed by cytokines, 28 other Madrid, Spain) was administered half an hour before the start investigators have found no significant differences [22] [23] [24] [25] [26] and of CY and continued for the following 24 h. In this group have suggested that PBPC mobilization with the use of a all patients were hospitalized during the administration of growth factor alone could be beneficial, avoiding unnecess-HD-CY and during the subsequent aplasia. ary hospitalization and toxicity during the secondary aplarhGM-CSF (Molgramostim, Sandoz SA/Scheringsia induced by HD-CY. In spite of this controversy, only
Plough, E. coli unglycosylated product, Basel, Switzerland) a few studies, comparing both mobilization methods in at a dose of 8 g/kg/day subcutaneously, was started 24 h myeloma patients, have been reported.
after the last day of chemotherapy and continued until the In this paper we report our experience with 40 symptolast day of leukapheresis. In this group all patients were matic MM patients autografted with PBPC collected after hospitalized during the administration of HD-CY and durmobilization with G-CSF alone or with HD-CY plus GMing the subsequent aplasia. No antibiotics were given for CSF. We have compared the PBPC mobilization capacity bowel decontamination. At the onset of fever Ͼ38.5°C of these two different methods. Toxicity of both mobilizbroad spectrum i.v. antibiotics were administered. Packed ation regimens and data on hematological reconstitution red blood cells were transfused when the hemoglobin level following HDT were also studied in these patients.
was less than 8 g/dl and platelets were administered when platelet counts were below 20 × 10 9 /l. Collections were commenced after aplasia recovery, when the WBC reached a level greater than 1 × 10 9 /l.
Patients and methods
In group II (22 patients), progenitor cells were mobilized by using rhG-CSF alone (Filgrastim, unglycosylated, Amgen, Thousand Oaks, CA, USA) at a dose of Eligibility criteria 10 g/kg/day s.c. The cytokine was given until the end of collection, starting the leukaphereses on the 5th day. Between January 1991 and August 1995, 40 consecutive
The first mobilization method was used from January patients with MM were included in this study. Inclusion 1991 to December 1993 and the second method was used criteria were as follows: age Ͻ65 years, stage II or III at from January 1994 to August 1995. diagnosis according to the Durie-Salmon classification and
Harvesting was performed with a continuous flow cell non-refractoriness to standard treatment. Eligibility criteria separator (COBE-Spectra; COBE, Denver, CO, USA). The also included an acceptable performance status (Ͻ3) and automated program of lymphocytopheresis was modified adequate organ function (creatinine clearance у50 ml/min, with a collection rate of 0.9 ml/min. Each subsequent prodiffusion lung capacity у50% of predicted and left vencedure took place 12 h after the preceding dose of cytokine. tricular ejection fraction у50%).
For each leukapheresis, 10-15 l blood were processed at a All patients signed an informed consent before PBPC flow rate 50-80 ml/min without significant differences in mobilization and transplantation. The study was performed both groups. A large-bore polyurethane catheter (Quintonunder the ethical guidelines of the Committee of Clinical Mahurkar catheter; Quinton Instruments Co, Seattle, WA, Investigation of the Universitary Hospital de la Princesa, USA), was used for central venous access in most patients. in Madrid and the Local Ethical Committee.
The catheter was inserted on a short-term basis, specifically for PBPC harvesting. The characteristics of this venous access, the technique of insertion and its complications Patients have been recently described by our group. 29 Patients' clinical characteristics are summarized in Table 1 . PBPC cryopreservation The median age was 48 years (33-60) in group I and 49 (27-59) in group II. Before mobilization, 16 cases were in Peripheral stem cells were volume adjusted to a final concentration of Ͻ1 × 10 8 WBC/ml. An equal volume of auto-PR and two in CR in group I, and 16 were in PR and six in CR in group II. Median numbers of previous chemotherapy logous plasma or minimum essential medium containing 20% dimethyslulfoside (DMSO) (Sigma Chemical Co, St courses were 11 (6-36) and nine (4-25) for group I and group II respectively (P = NS), and median periods from Louis, MO, USA) was mixed with the apheresis product to yield a final concentration of 10% DMSO. The final suspendiagnosis were 18 months (6-58) for group I and 11 months (5-96) for group II (P = NS). The number of patients with sion was transferred into freezing bags and frozen to −100°C, using a computer controlled device (Cryoson previous radiation, five for group I and seven for group II and the median duration of previous alkylating chemo-MYC 15, Cryoson Deutschland, Germany; or Congelador 25 L, Carburos Metálicos, Madrid, Spain) and stored in therapy, 6 months for group I (0-22) and 4 months (0-19) for group II, showed no significant differences.
liquid nitrogen at −196°C following standard methods.
213 Table 1 Main characteristics of patients included in the study Spain) were used for statistical analysis. Differences in Granulocyte-macrophage progenitor cells (colony-forhematological parameters and patient characteristics were ming unit granulocyte-macrophage, CFU-GM) were anatested using the Mann-Whitney U-test. The Wilcoxon rank lyzed in each apheresis product. Fresh viable peripheral sum test (two-sided) was used to compare cell yields and blood cells (2 × 10 5 ) were plated in triplicate using a stanrecovery rates. A P value of Ͻ0.05 was considered signifidard method. Cultures were incubated in a closed humidicant. Time to recovery of granulocytes and platelets postfied atmosphere at 37°C with 5% CO 2 and colonies of grantransplantation was estimated, from the date of infusion ulo-monocytic cells (Ͼ40 cells) were scored after 14 days. until recovery, using the Kaplan-Meier product limit CD34 + cells in the leukapheresis product were enumermethod. 32 Results were compared between groups using the ated by flow cytometry (FACScan; Becton Dickinson, San log-rank test. José, CA, USA) using direct CD34 immunofluorescence. A minimum of 1 × 10 6 MNC were incubated for 30 min at 4°C with fluorescence conjugated (8G12, anti-HPCA-1, conjugated either to fluorescein isothiocyanate, FITC or RResults phycoerythrin (PE; Becton Dickinson). Data were analyzed on the 'lymphoid' population, characterized by low rightMobilization regimen toxicity and leukaphereses angle light scatter and low-to-intermediate forward light scatter. A minimum of 10 000 events were counted in the In the group I, mobilized with HD-CY followed by GM-CSF, the median interval between the last day of chemo-'lymphocyte' gate. The gated percentage of CD34 + cells was multiplied by the absolute MNC (lymphocytes plus therapy and the first apheresis was 13 days (8-21). GM-CSF was administered in this group for a median of 15 monocytes) of the apheresis product to yield an absolute CD34 + cell count for each apheresis. More details of days (10-25). All patients included in this group were hospitalized during the subsequent aplasia for a median period clonogenic assays, immunofluorescence staining and flow cytometry have been previously reported. 30, 31 of 21 days (16-34). Twelve patients (66%) presented fever Ͼ38.5°C in the neutropenic phase (Ͻ0.5 × 10 9 /l) requiring antibiotics that were administered during a median of 7 Transplantation procedure days (6-15). Documented septicemia occurred in two patients, one attributed to Staphylococcus epidermidis and The ablative regimen consisted of busulfan (Busulfano; Wellcome, Madrid, Spain) 1 mg/kg p.o. every 8 h for 12 doses the other to Streptococcus viridans. This case was complicated with reversible septic shock symptoms. The mean on days −6 to −3 (total dose of 12 mg/kg) and melphalan generalized bone pain requiring analgesia (paracetamol).
Mobilization method HD-CY + GM-CSF G-CSF alone (group I) (group II)
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Results are expressed as median (range).
G-CSF stimulation in group II was applied in an outpatient setting during a median of 7 days (6-11). G-CSF was well-tolerated in all patients except for mild musculoskeletal bone pain occurring in 10 patients with only three cases requiring analgesia (paracetamol).
In group I the mobilization results per patient were: No fatal toxicity was observed in any patients during the MNC × 10 8 /kg 7.35 (6.9-11.6),CFU-GM × 10 4 /kg 4.1 (0.9-mobilization phase. Toxicity of both PBPC mobilization 66) and CD34 + cells × 10 6 /kg 6.8 (1.8-34.8). regimens and supportive therapy are summarized on
In group II the overall results were: MNC × 10 8 /kg 8.59 Table 2 .
(6.4-11.3),CFU-GM × 10 4 /kg 2.33 (0.5-24.2) and CD34 × 10 6 /kg 4.85 (2.1-10.05). The overall yields of CD34 + cells obtained per patient Progenitor yields in group I was significantly higher (P = 0.04). These results In group I, the median value yields per pheresis were: MNC are summarized in + cells per pheresis group I and 11 (range 7-42) for group II. The median time were yielded in group I, after chemotherapy priming, to platelet (Ͼ20 × 10 9 /l) was 11 days (range 10-16) for (P = 0.02). The rest of the mobilization values showed no group I and 13 days (range 10-38) for group II. No signifisignificant differences (Table 3) . cant differences were observed between both groups The median number of aphereses performed in each regarding hemopoietic engraftment (Table 5) . group was five (4-12) with a mean of 5.24 ± 2.51 in the Hematological reconstitution after PBPC transplantation, group I and three (2-5) with a mean of 3.1 (±0.91) in group II (P = NS). Table 5 Hemopoietic recovery after transplant Table 3 Results of mobilization methods per pheresis 40 The doses applied have been different, ranging in general from 5 to 10 g/kg. Toxicity of groups in Figure 1 .
this hemopoietic growth factor has been reported to be greater than that of G-CSF after HD-CY on a randomized study performed by Demuynck et al. 19 In this study both Discussion cytokines were used at the same dose (10 g/kg/day) and GM-CSF resulted in delayed hemopoietic recovery and Mobilization of PBPC can be a major problem in patients with MM who are candidates for autologous PBPC transincreased complication rate. Kelsey et al 14 have reported that GM-CSF at a dose of 5 g/kg/day following HD-CY, plantation. However, collection of an adequate number of cells is mandatory for significant reduction of toxicity dur-4 g/m 2 , may be as effective as 10 g/kg/day and avoids the toxicity associated with the higher dose. In our series, we ing the transplant. Patient conditions affect the mobilization and collection of PBPC in most cases. These aspects have use a lower dose of GM-CSF, 8 g/kg, which was well tolerated in most patients with no need for discontinuation, been recently reported by Tricot et al, 16 Prince et al 33 and Demirer et al 34 in myeloma patients and by Chabannon et although some patients presented reversible side-effects.
To avoid morbidity and to cut down expenses some al, 25 Haas et al 35 and Bensinger et al 36, 37 in patients with other diseases. Disease status, extent of previous therapy authors 21, 41 have reduced the dose of CY between 1.5 g/m 2 and 3 g/m 2 . To avoid a suboptimal dose, these authors have and history of prior irradiation have an adverse effect on the number of CD34 + cells collected. These reasons may increased the dose of G-CSF used after CY to 10 g/kg/day. Although more studies are necessary, these have influenced the unsuccessful collections observed in different series of myeloma patient.
14-17,25,33 The probauthors found efficient PBPC mobilization with this regimen and no patient required hospitalization or transfusion ability of collecting an adequate number of PBPC also increases when the mobilization is performed early in the support.
In an attempt to further simplify the PBPC mobilization course of the disease without prior melphalan therapy. 33 HD-CY efficiently mobilizes PBPC, 17-20,37,38 however, and collection procedures, G-CSF is increasingly used alone without previous chemotherapy priming in patients while increasing the dose enhances the yields proportionally, 19 the optimal dose is not well-defined. Some with nonmyeloid malignancies or solid tumors. However, the use of G-CSF alone as mobilizing agent in myeloma authors have found CY 7 g/m 2 as the optimal regimen 18,19,39 but infections and long-lasting thrombocytopenia, requiring during steady-state hematopoiesis is controversial. The dose of G-CSF used ranged from 5 g/kg/day to platelet transfusions during the secondary aplasia, are predictable in an important number of patients. Other authors 25 g/kg/day. Most authors have used the standard dose of 10 g/kg/day 15,16,19,20-26 although a dose effect has been have used CY 4 g/m 2 followed by hemopoietic growth factors in myeloma patients and have observed mobilization observed, and as suggested by Demirer et al 34 higher dose of G-CSF (16-32 g/kg/day) can result in adequate CD34 + of an adequate number of PBPC, but also with important complications. 20, 21, 37 In our series we have used CY 4 g/m 2 cell collections in some secondary attempts in patients with MM failing an initial mobilization regimen. Several reports and have found 12 cases (66%) who developed fever greater than 38.5°C requiring i.v. antibiotics during the neusuggest a lower rate of 'mobilizing failures' in myeloma patients after priming with chemotherapy but there are tropenic period, with two cases of documented septicemia one of them complicated with septic shock symptoms, and recent publications indicating that mobilization with a low dose of G-CSF alone is feasible in these patients. [22] [23] [24] 34 six cases who required platelet support. GM-CSF is a hemopoietic growth factor increasingly There have been reports indicating that G-CSF can stimulate the growth of plasma cells 42, 43 and some authors used to prime and collect PBPC after HD-CT with effihave demonstrated concomitant mobilization of tumor cells and hemopoietic progenitors in the PB of MM patients by using CY plus G-CSF or G-CSF. 10, 44, 45 However, an increase in PB tumor contamination after mobilization with G-CSF has not been detected by using molecular methods 8, 9 in comparison with bone marrow. Although some authors have suggested that there is no effect on the presence of tumor cells in the harvest product in response to transplant therapy 45 other authors have demonstrated association of the monoclonal plasma cells in the blood stem cells harvest with shortened relapse-free survival after transplantation. 44 Attempts are now being made to positively select hemopoietic from malignant myeloma cell progenitors in stem cell collections but results are still preliminary. [46] [47] [48] Moreover, the biological and prognostic significance of plasma cells in PBPC collections is still unknown and the most relevant esis is achieved with chemotherapy followed by hemopo- achieved in most patients in our series by using G-CSF that the use of G-CSF alone is a feasible method for mobil-504-505.
izing PBPC in myeloma patients with obvious advantages. 
